|
|
Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis |
|---|---|
| Author: | Mälkönen, Tarja1; Nuutinen, Pauliina1; Hallinen, Taru2; |
| Organizations: |
1Skin and Allergy Hospital, Helsinki University Hospital, Helsinki 2ESiOR Oy, Kuopio 3Janssen-Cilag Oy, Espoo, Finland
4Janssen-Cilag, Sweden
5Infoderm Oy, Tampere 6Vaasa Central Hospital, Vaasa 7Department of Dermatology, Turku University Hospital, Turku 8Department of Dermatology, Kuopio University Hospital and University of Eastern Finland, Kuopio 9HUS Helsinki University Hospital, Lohja Hospital, Lohja 10Department of Dermatology, Mikkeli Central Hospital, Mikkeli 11Department of Dermatology and Allergology, Ålands Central Hospital, Maarianhamina 12Department of Dermatology, Keski-Suomi Central Hospital, Jyväskylä 13PEDEGO Research Unit, University of Oulu, Oulu; Department of Dermatology and Medical Research Center, Oulu University Hospital, Oulu 14Department of Dermatology, Savonlinna Central Hospital, Savonlinna 15Department of Dermatology and Allergology, Kanta-Häme Central Hospital, Hämeenlinna 16Department of Dermatology, Päijät-Häme Central Hospital, Lahti 17Department of Dermatology and Venereology, Kainuu Central Hospital, Kajaani 18Department of Dermatology, Mehiläinen Länsi-Pohja, Kemi 19Department of Dermatology, Tampere University Hospital and Tampere University, Tampere, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.7 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2022051836667 |
| Language: | English |
| Published: |
Society for Publication of Acta Dermato-Venereologica,
2022
|
| Publish Date: | 2022-06-28 |
| Description: |
AbstractGuselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting. see all
|
| Series: |
Acta dermato-venereologica |
| ISSN: | 0001-5555 |
| ISSN-E: | 1651-2057 |
| ISSN-L: | 0001-5555 |
| Volume: | 102 |
| Article number: | adv00631 |
| DOI: | 10.2340/actadv.v101.910 |
| OADOI: | https://oadoi.org/10.2340/actadv.v101.910 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3121 General medicine, internal medicine and other clinical medicine |
| Subjects: | |
| Funding: |
This study was supported by Janssen-Cilag Oy (Finland). |
| Copyright information: |
Copyright (c) 2021 Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work. |
|
https://creativecommons.org/licenses/by-nc/4.0/ |